Chinese expert consensus on multigene testing for postoperatively adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer

Abstract

Breast cancer is the most common malignant tumor in women, of which early-stage (stages Ⅰ-Ⅱ) breast cancer (EBC) accounts for 73.1%. The strategy of postoperative adjuvant treatment relies mainly on the clinicopathologic characteristics of patients, but there are certain deficiencies in the assessment of treatment benefits and disease prognosis. Multigene testing tools can evaluate the prognosis and predict therapeutic effects of breast cancer patients to guide the clinical decision-making on whether to use adjuvant chemotherapy, radiotherapy, and endocrine therapy by detecting the expression levels of specific genes. The consensus-writing expert group, based on the characteristics, validation results, and accessibility of the multigene testing tools and combined with clinical practice, described the result interpretation and clinical application of OncotypeDx(®) (21-gene), MammaPrint(®) (70-gene), RecurIndex(®) (28-gene), and BreastCancerIndex(®) (BCI, 7-gene) for hormone receptor-positive and human epidermal growth factor receptor 2-negative EBC. The development and validation process of each tool was also briefly introduced. It is expected that the consensus will help to guide and standardize the clinical application of multigene testing tools and further improve the level of precise treatment for EBC.